Key 2023 Milestones: Present the first detailed results from the Targeted Therapeutics program device performance study indicating successful device function when administered with food, which could potentially enable non-fasted administration in patients, at the Crohn’s & Colitis Congress on January 19, 2023. File an IND for Targeted Therapeutics PGN-600 and enter the clinic in the first half of 2023. Generate key Targeted Therapeutics PGN-600 data by Q3. Complete Systemic Therapeutics preclinical data generation with the next generation device in Q1 and Q2. Initiate next-phase pharma partnerships for Systemic Therapeutics program in 2023. Biora also remains committed to efficient use of resources by maintaining its target monthly cash burn rate while rapidly progressing development.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIOR:
- Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
- Biora Therapeutics Announces Reverse Stock Split
- Biora Therapeutics announces 25-to-1 reverse stock split
- Biora licenses preeclampsia rule-out test for commercial development
- Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
